权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Identification and characterization of novel drugs that target the Influenza

针对流感的新药的鉴定和表征

基本信息

批准号：
9217553
负责人：
RICHARD J. WHITLEY
金额：
$ 104.47万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-03-01 至 2019-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9217553
关键词：
Alabama Amantadine Antiviral Agents Antiviral Therapy Biological Assay Biological Availability Birds Chemicals Chemistry Complement Complex Coupled DNA-Directed RNA Polymerase Development Drug Kinetics Effectiveness Epidemic Escape Mutant Exclusion Experimental Designs Frequencies Genetic Transcription Glycoproteins Goals House mice In Vitro Incidence Infection Influenza Influenza A Virus, H1N1 Subtype Influenza A virus Instruction Interferon Inducers Lead Libraries Life Cycle Stages Modeling Mutagenesis Mutation Neuraminidase inhibitor Pathogenicity Pharmaceutical Preparations Pharmacotherapy Phenotype Polyadenylation Polymerase Process Property Proteins Publishing RNA replication RNA-Directed RNA Polymerase RNA-Protein Interaction Research Resistance development Specificity Structure Therapeutic Triage Universities Viral Viral Physiology Virus Virus Diseases Virus Replication base drug development drug discovery effective therapy endonuclease global health high throughput screening in vivo influenza epidemic influenza virus strain influenzavirus inhibitor/antagonist mouse model mutant new therapeutic target novel novel therapeutics nucleoside inhibitor pandemic disease reconstitution resistance mutation scaffold screening small molecule small molecule libraries

项目摘要

The overall goal of this project is to identify new therapies that target influenza virus replication. The global health burden of annual influenza epidemics coupled with the emergence of highly pathogenic strains of influenza virus has highlighted the urgent need for new effective treatments A primary concern with the current drugs (amantadines and neuraminidase inhibitors) used to treat influenza is the development of resistance mutations that negate therapeutic benefit. Published evidence suggests that targeting the influenza virus RNA dependent RNA polymerase (RdRp) is a rational approach for antiviral therapy. The RdRp is responsible for a number of functions including 5'cap recognition, endonuclease activity, replication, transcription, and polyadenylation. Recently, cryo-EM reconstitution studies identified branchedribonucleoproteins (RNPs) structures as putative replication interhiediates and suggested a mechanism for viral replication by a second polymerase activity on the RNP template . The second polymerase activity is believed to be a function ofthe polymerase complex. Clearly, the RdRp provides multiple functional domains that could be targets for antiviral drug therapy. Previous studies showed that mutations in the conserved regions of PB1 subunit of the polymerase complex produce inactive RNA polymerase. We hypothesize that compounds that specifically target the polymerase complex might reduce the frequency of escape mutations, or promote escape mutants that are unfit for replication. We have recently identified potential hit compounds from previous HTS screens that significantly inhibit the influenza virus polymerase activity in an RdRp transient assay. These hit compounds were effective against three different strains of influenza viruses in CPE assays. We propose to characterize these compounds and use high-throughput screening (HTS) of novel small molecule libraries to identify anti-polymerase candidate compounds, chemically optimize them, and establish their effectiveness in an influenza mouse model. \

该项目的总体目标是确定针对流感病毒复制的新疗法。每年流感流行的全球健康负担，加上高致病性流感病毒株的出现，突出了对新的有效治疗的迫切需要。目前用于治疗流感的药物（金刚烷胺和神经氨酸酶抑制剂）的主要问题是产生耐药性突变，从而否定治疗益处。已发表的证据表明，靶向流感病毒RNA依赖性RNA聚合酶（RdRp）是抗病毒治疗的合理方法。RdRp负责许多功能，包括5 '帽识别、核酸内切酶活性、复制、转录和聚腺苷酸化。最近，cryo-EM重建研究确定branchedribonucleoproteins（RNP）的结构作为假定的复制interhiediates，并建议通过第二聚合酶活性的RNP模板的病毒复制的机制。第二种聚合酶活性被认为是聚合酶复合体的功能。显然，RdRp提供了多个功能结构域，可以作为抗病毒药物治疗的靶点。先前的研究表明，在聚合酶复合物的PB 1亚基的保守区域中的突变产生失活的RNA聚合酶。我们推测，特异性靶向聚合酶复合体的化合物可能会降低逃逸突变的频率，或促进不适合复制的逃逸突变体。我们最近从以前的HTS筛选中鉴定出潜在的命中化合物，其在RdRp瞬时测定中显著抑制流感病毒聚合酶活性。这些命中化合物在CPE测定中有效对抗三种不同的流感病毒株。我们建议对这些化合物进行表征，并使用新型小分子文库的高通量筛选（HTS）来鉴定抗聚合酶候选化合物，对其进行化学优化，并在流感小鼠模型中建立其有效性。 \